News & Events Archive

2018

December 27, 2018Suven Life Sciences secures Product Patents in Brazil and EurasiaView PDF
November 30, 2018Suven Life Sciences is giving corporate presentation in B&K's Investor Conference Emergent IndiaView PDF
November 13, 2018Suven Life Sciences secures Product Patents in Australia and Hong KongView PDF
November 06, 2018Suven Life Sciences secures Product Patents in Israel and JapanView PDF
November 05, 2018Suven Life sciences presenting at Neuroscience 2018 at San Diego, USA.View PDF
October 25, 2018Suven Life Sciences Ltd Announces the last patient enrolled in Phase 2 study of SUVN-502 for ModeratView PDF
October 23, 2018Suven to present at 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) during OCTOBER 24-27, 2018 -View PDF
September 25, 2018Suven Life Sciences secures Product Patents in Canada and Sri LankaView PDF
September 14, 2018Suven Life Sciences secures Product Patents in New Zealand and Sri LankaView PDF
August 29, 2018Suven Life Sciences secures Product Patents in China & EurasiaView PDF
August 22, 2018Suven Life Sciences secures Product & Process Patents in Canada and USAView PDF
August 07, 2018Suven Life Sciences secures Product Patents in Mexico and New ZealandView PDF
July 23, 2018Suven at Alzheimer's Association International Conference (AAIC) in Chicago.View PDF
July 16, 2018Suven Life Sciences secures Product Patents in Europe and South KoreaView PDF
July 04, 2018Suven Life Sciences secures Product Patents in India, Singapore, South Korea and IsraelView PDF
June 12, 2018Suven Life Sciences secures Product Patents in China and USAView PDF
June 08, 2018Suven Life Sciences is participating and presenting in Jefferies Global Healthcare ConferenceView PDF
June 01, 2018Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA.View PDF
May 29, 2018Suven Life Sciences secures Product Patents in New Zealand and USAView PDF
May 22, 2018Suven Life Sciences secures Product Patents in New Zealand and NorwayView PDF
May 17, 2018Suven Life Sciences secures Product Patents in Australia and SingaporeView PDF
May 15, 2018Suven Revenue up by 15%; PAT up by 28% for the year ended March 2018View PDF
May 10, 2018Q4 FY18 Schedule of conference call for InvestorsView PDF
May 09, 2018Suven Life Sciences secures Product Patents in Australia, Eurasia and EuropeView PDF
May 07, 2018SUVEN’S Pashamylaram’s Unit Successfully completes US FDA InspectionView PDF
April 24, 2018USFDA InspectionView PDF
April 03, 2018Suven Life Sciences secures a Product Patent in Canada.View PDF
March 22, 2018Suven Life Sciences secures Product Patents in Norway, South Korea, and Singapore.View PDF
February 20, 2018Suven Life Sciences secures Product Patents in India and South KoreaView PDF
January 31, 2018Q3 & 9MFY18 Conference Call TranscriptView PDF
January 31, 2018Suven Life Sciences secures Product Patents in Aripo and South KoreaView PDF
January 30, 2018Suven Revenue up by 11.85%; PAT up by 15.38% for 9 months ended December’ 2017View PDF
January 25, 2018Q3 FY18 Schedule of conference call for InvestorsView PDF
January 18, 2018Suven Life Sciences secures Product Patents in China and Sri LankaView PDF

2017

December 21, 2017Suven Life Sciences secures Product Patents in Canada and IndiaView PDF
December 11, 2017B&K's Investor Conference Emergent India-2017View PDF
December 11, 2017Suven Life Sciences secures Product Patents in India and USAView PDF
December 06, 2017Suven Life Sciences secures Product Patents in Eurasia and NorwayView PDF
November 16, 2017Suven Life secures Product Patents in HongKong, India and USAView PDF
November 13, 2017Suven Life sciences presenting at Neuroscience 2017 at Washington DCView PDF
November 11, 2017Suven Income at INR 2586 Mn; PAT at INR 613 Mn for the half year ended September 2017View PDF
October 18, 2017Suven Life Sciences secures a Product Patent in SingaporeView PDF
October 13, 2017Intimation of sad Demise of Director Dr. K.V. RaghavanView PDF
October 10, 2017Suven Life Sciences secures a Product Patent in New ZealandView PDF
September 25, 2017Suven Life Sciences secures Product Patents in India and JapanView PDF
August 21, 2017Suven Life secures a Product Patent in JapanView PDF
August 17, 2017Suven Life secures Process Patents in Europe, Japan and New ZealandView PDF
August 14, 2017Suven’s Income at Rs. 1466 Mn; PAT at Rs. 295 Mn for the quarter ended June 2017View PDF
July 21, 2017Suven Life secures a Product Patent in AustraliaView PDF
July 14, 2017Suven at Alzheimer's Association International Conference (AAIC) in LondonView PDF
July 10, 2017Suven Life secures Product Patents in Israel, Macau and South KoreaView PDF
June 13, 2017Suven Life secures a Product Patent in Australia and USAView PDF
June 03, 2017Suven Team is participating in B&K's Annual Conference 'Trinity India 2017' on June 5, 2017 - MumbaiView PDF
May 30, 2017Annual Investor Conference "Centrum Corporate Connect - 2017 with fund managers and analysts meet orView PDF
May 25, 2017Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a NView PDF
May 13, 2017Suven Revenue up by 9%; PAT up by 23% for the year ended March 2017View PDF
May 11, 2017Q4FY17 Schedule of conference call for InvestorsView PDF
March 28, 2017Suven Life secures a Product Patents in New ZealandView PDF
February 03, 2017Suven Team is participating in "ICICI Securities’ Annual Investor Conference 2017" on 6th – 7th FebrView PDF
February 01, 2017Suven Revenue up by 9.98%; PAT up by 32.77% for 9 months ended December 2016View PDF
January 30, 2017Q3FY17 Schedule of Conference Call for InvestorsView PDF
January 30, 2017Suven Life Sciences secures a Product Patent in USAView PDF
January 23, 2017Suven Life Sciences secures a Product Patent in AustraliaView PDF
January 11, 2017SuvenInc is presenting at Biotech Showcase™ 2017 on 11th January and attending 35th Annual J.P. MorgView PDF
January 03, 2017Suven Life Sciences secures two (2) Product Patents in Eurasia and NorwayView PDF

2016

December 08, 2016Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE(CTAD) Conference held during DecemberView PDF
December 07, 2016Suven Life Sciences secures one (1) Product Patent in IndiaView PDF
November 24, 2016Suven Revenue growth at 13.42%; PAT up by 29.15% for the half year ended Sept, 2016View PDF
November 22, 2016Q2FY17 Schedule of Conference Call for InvestorsView PDF
November 22, 2016Suven Life Sciences secures two (2) Product Patents in China and MexicoView PDF
November 15, 2016Suven Life Sciences is participating and presenting in “Jefferies London Healthcare Conference “, LoView PDF
November 14, 2016Suven Life Sciences presenting at Society for Neuroscience (SFN-2016) San Diego.View PDF
October 18, 2016Suven Life Sciences secures two (2) Product Patents in Europe and IsraelView PDF
September 26, 2016Suven Life Sciences secures two (2) Product Patents in India and JapanView PDF
September 08, 2016Suven Life secures three (3) Product Patents in Canada, Europe and Hong KongView PDF
August 10, 2016Q1FY17 Schedule of Conference Call for InvestorsView PDF
August 10, 2016Suven’s Income at Rs. 1377 Mn; PAT at Rs. 326 Mn for the 1st quarter ended June 2016View PDF
August 01, 2016Suven Life secures two (2) Product Patents in Macau and New ZealandView PDF
July 25, 2016Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
July 21, 2016SUVEN’S Pashamylaram’s Unit Successfully completes US FDA InspectionView PDF
July 12, 2016Suven Life secures two (2) Product Patents in India and South AfricaView PDF
June 29, 2016Suven Life secures three (3) Product Patents in Europe and EurasiaView PDF
June 14, 2016Suven Life Sciences secures two (2) Product Patents in Canada and Hong KongView PDF
June 03, 2016Suven Life Sciences secures two (2) Product Patents in Israel and MexicoView PDF
May 31, 2016Suven Team is participating in "Annual Investors Conference Trinity India-2016" on June 1stView PDF
May 30, 2016Q4FY16 Schedule of Conference Call for InvestorsView PDF
May 27, 2016Suven Revenue up by 49.21%; PAT up by 83.23% for the Fourth quarter ended March 2016View PDF
May 23, 2016Suven Life Sciences secures 4 (four) Product Patents for their NCE's in Australia, Eurasia, Israel aView PDF
April 04, 2016Suven to Present at Bio-Europe Spring 2016 conference being held at Stockholm, Sweden.View PDF
March 14, 2016Suven Life secures three (3) Product Patents in China, Eurasia and Hong KongView PDF
March 09, 2016Investors Meet on 10th & 11th March, 2016View PDF
March 07, 2016Investor Conference Call on 8th March, 2016View PDF
February 19, 2016Suven Life Sciences secures two (2) Product Patents in Australia and CanadaView PDF
February 12, 2016Suven Revenue down by 4.96%; PAT down by 28.34% for the Third quarter ended December, 2015View PDF
January 11, 2016Suven Inc is presenting at Biotech Showcase™ 2016 and participating in the 34th Annual J.P. Morgan HView PDF
January 05, 2016Suven Life Sciences secures three (3) Product Patents in Canada, ARIPO and South KoreaView PDF

2015

December 29, 2015Suven Life Sciences secures Two (2) Product Patents in Europe and MacauView PDF
December 23, 2015Suven Life Sciences secures 7 (seven) Product Patents for their NCE’s in ARIPO, Europe, Hong Kong, JView PDF
December 14, 2015Suven Life Sciences at Centrum Pharma Day Mumbai for analysts’ meetView PDF
December 11, 2015Suven Life secures four (4) Product Patents in Eurasia, Europe, Israel and MacauView PDF
December 07, 2015Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer’s DiseaseView PDF
November 10, 2015Suven Revenue growth at 15.55%; PAT up by 22.23% for the Second quarter ended Sept, 2015View PDF
November 05, 2015Suven to Present at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during NOVEMBEView PDF
November 02, 2015Suven to Present at Bio-Europe 2015 Partnering conference held during November 2 - 4, 2015 in MunichView PDF
October 19, 2015Suven Life Sciences at Society for Neuroscience (SFN-2015) Chicago. Presenting data on several of thView PDF
October 13, 2015Suven Life Sciences secures 5 (five) Product Patents for their NCE’s in Australia, China, Europe, SoView PDF
September 28, 2015Suven Life secures three (3) Product Patents in New Zealand, Singapore and USAView PDF
September 16, 2015Suven Life Sciences secures Three (3) Product Patents in Canada and ChinaView PDF
September 10, 2015Suven Life Sciences secures five (5) Product Patents in China, Israel, Mexico, Singapore and Sri LanView PDF
September 02, 2015SUVN-D4010 for Cognition in Alzheimer’s disease commenced Phase 1 Clinical Trial in USA under US-INDView PDF
August 14, 2015Suven’s Income lower by 7.35%; PAT increase by 19.36% for the quarter ended June 2015View PDF
July 17, 2015Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
July 13, 2015Suven Life Sciences secures 4 (four) Product Patents for their NCE’s in China, Mexico and South AfriView PDF
June 30, 2015Suven Life Sciences secures Three (3) Product Patents in Israel, Japan and South AfricaView PDF
June 16, 2015Suven Life secures Three (3) Product Patents in Israel, Macau and USAView PDF
May 26, 2015Suven’s Income increased by 3% and PAT lower by 25% for the year ended March 2015View PDF
May 22, 2015Suven Life secures One (1) Product Patent each in Mexico and SingaporeView PDF
May 13, 2015Suven Life secures Two (2) Product Patents in Europe and Hong kongView PDF
April 24, 2015Suven Life secures Five (5) Product Patents for their NCEs in Australia, Europe, Hong kong, Israel aView PDF
April 13, 2015Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigatView PDF
March 24, 2015Suven Life secures Three (3) Product Patents for their NCEs in Canada, Japan and KoreaView PDF
March 16, 2015Suven Life Sciences secures 2 (two) Product Patents for their NCE’s through New mechanism of actionView PDF
March 09, 2015Suven Life secures One (1) Product Patent each in Eurasia and IsraelView PDF
February 16, 2015Suven Life Sciences secures 4 (four) Product Patents for their NCE’s through New mechanism of actionView PDF
February 10, 2015Suven Revenue growth at 9% while PAT is down by 11.55% for the 3rd Quarter ended Dec 2014View PDF
January 20, 2015Suven Life secures One (1) Product Patent each in Australia & Hong Kong, two (2) product patents froView PDF

2014

December 30, 2014Suven Life secures three (3) Product Patents in Eurasia, Japan, and MexicoView PDF
December 30, 2014Suven Life secures three (3) Product Patents in Eurasia, Japan, and MexicoView PDF
December 12, 2014Suven Life secures (5) Product Patents for their NCEs in Israel, Japan, China and New ZealandView PDF
December 03, 2014Suven Life Sciences Limited Raises INR 200 Cr Through a Qualified Institutions Placement (QIP)View PDF
November 17, 2014Q2 FY15 Conference Call TranscriptView PDF
November 14, 2014Suven Revenue growth at 7.8% while PAT is down by 20% for the half year ended Sept, 2014View PDF
November 03, 2014SUVN-G3031 for Cognition in Alzheimer’s Disease commenced Phase 1 Clinical Trial in USA under US-INDView PDF
October 13, 2014Suven Life secures One (1) Product Patent in South Korea and one (1) from USAView PDF
October 07, 2014Suven Life Sciences is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014.View PDF
September 23, 2014Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export PerformaView PDF
September 03, 2014Suven Life Sciences secures (3) Product Patents for their NCEs in South Korea, China and CanadaView PDF
August 12, 2014Suven achieved a PAT of Rs.34.73 Crores for first Qtr of 2014-15, an increase of 16.68% compared toView PDF
August 06, 2014Suven Life secures (2) Product Patents for their NCEs in Australia and EurasiaView PDF
July 11, 2014Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
June 04, 2014Suven Life secures One (1) Product Patent in USAView PDF
May 26, 2014Suven Investor/Analyst Conference Call TranscriptView PDF
May 22, 2014Suven’s PAT up by 367% for the year ended March 2014 & proposed regular and one time special silverView PDF
May 19, 2014Suven Life secures (3) Product Patents in Australia, South Korea and ChinaView PDF
April 10, 2014Suven Life secures (2) Product Patents for their NCEs in Canada and Hong KongView PDF
April 03, 2014Suven Life Sciences secures 4 Product Patents for their NCEs in China and KoreaView PDF
March 26, 2014Suven Life secures (2) Product Patents for their NCEs in USAView PDF
March 04, 2014Suven grants an exclusive license & right to distribute its Malathion Lotion in USA, CANADA and MEXIView PDF
February 14, 2014Suven Life secures (2) Product Patents for their NCEs in New ZealandView PDF
February 06, 2014Suven Investor/Analyst Conference Call TranscriptView PDF
February 04, 2014Suven Q3 PAT up by 370% to Rs.36.43 CrView PDF
January 31, 2014Suven Life secures (3) Product Patents for their NCEs in Canada, China and IndiaView PDF
January 22, 2014SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCEView PDF
January 09, 2014Suven Life secures three (3) Product Patents for their NCEs in Australia, Sri Lanka and South KoreaView PDF

2013

November 13, 2013Suven Investor/Analyst Conference Call TranscriptView PDF
November 11, 2013Suven Q2 PAT up by 602% to Rs.45.55 CrView PDF
November 08, 2013Suven Life Sciences presenting the positive pharmacology data of 4 NCEs at Society for NeuroscienceView PDF
September 25, 2013Suven Life secures three (3) Product Patents for their NCEs in New Zealand, Singapore and South KoreView PDF
August 13, 2013Suven Q1 PAT up by 274% to Rs.29.77 CrView PDF
August 08, 2013Suven Life secures two (2) Product Patents for their NCEs in EuropeView PDF
July 12, 2013Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
July 05, 2013Suven Life secures two (2) Product Patents for their NCEs in USA and JapanView PDF
June 28, 2013Suven Life Sciences secures two (2) Product Patents for their NCEs in Japan and USAView PDF
May 14, 2013Suven‘s PAT up by 115% for the year ended Mar 2013View PDF
May 10, 2013Suven Life Sciences secures three Product Patents for their NCEs in Canada and Eurasia.View PDF
April 17, 2013Suven Life Sciences secures 4 Product Patents for their NCEs in China, Mexico and New ZealandView PDF
February 12, 2013Suven‘s PAT up by 500 % for the quater ended Dec 2012View PDF

2012

December 31, 2012Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada.View PDF
December 13, 2012Suven Life Sciences secures 5 Product Patents for their NCEs in China & KoreaView PDF
November 15, 2012Suven‘s PAT up by 153% for the quarter ended 30th September’ 2012View PDF
October 04, 2012Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”View PDF
August 14, 2012Suven‘s PAT up by 137 % & Turnover up by 58 % for 1st Quarter ended 30th June 2012View PDF
August 09, 2012Suven Life Sciences secures 4 Product Patents for their NCEs in Australia, Canada, Korea and New ZeaView PDF
July 13, 2012Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
May 22, 2012Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and EurasiaView PDF
May 04, 2012Suven‘s PAT up by 137% for 4th Quarter ended 31st Mar’2012View PDF
February 07, 2012Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USAView PDF
January 31, 2012Suven‘s revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec’2011View PDF
January 11, 2012Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011View PDF

2011

December 08, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and CanadaView PDF
November 14, 2011Suven Life Sciences presenting the Pre-clinical data of their NCEs at Society for Neuroscience (SFN-View PDF
November 01, 2011Suven‘s revenue up by 31% and spends 18% of revenue on R&D;View PDF
October 04, 2011Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”View PDF
September 22, 2011Suven Participating at 4th CNS Partnering & Deal Making Conference in USAView PDF
September 05, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and New ZealandView PDF
August 18, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in the key markets in the worldView PDF
August 13, 2011Suven‘s revenue up by 24% and spends 17% of revenue on R&DView PDF
July 18, 2011Suven presenting at International Conference on Alzheimer’s disease (ICAD)View PDF
June 20, 2011Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the worldView PDF
May 30, 2011Suven Spends 20.5% of Revenue on R&D PAT up by 48.55% for the year ending March 2011View PDF
May 26, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in several key markets in the worldView PDF
May 18, 2011Suven’s Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) stuView PDF
May 09, 2011Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”View PDF
April 26, 2011Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the worldView PDF
April 05, 2011SUVEN’S UNIT-III RECEIVES US FDA ACCEPTANCEView PDF
January 31, 2011Suven spends 24% of revenue on R&D ;PAT up by 55% for for the 3rd quarter ending Dec 2010View PDF

2010

December 30, 2010Suven Life Sciences secures 2 Product Patents For Their NCEsView PDF
December 23, 2010Suven Life Sciences secures 4 Product Patents For Their NCEsView PDF
November 12, 2010Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual MeView PDF
October 27, 2010Suven spends 21% of revenue on R&D PAT up by 23% for the half yearView PDF
September 27, 2010Suven Life Sciences bags Pharmexcil's Gold “Patent Award”View PDF
September 21, 2010Suven Life Sciences secures Two US Patents on NCEsView PDF
September 08, 2010Suven Secures 8th product patent Both in Australia and MexicoView PDF
July 27, 2010Suven spends 22% of revenue on R&D PAT up by 58% for the 1st QuarterView PDF
July 12, 2010Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)View PDF
June 16, 2010Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE’View PDF
May 25, 2010Suven’s partnering and fundraising activity at C21 BioVentures™View PDF
May 12, 2010Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCEView PDF
May 03, 2010Prof. Syed Hasnain joins Suven as Additional DirectorView PDF
April 30, 2010Suven spends 26% of Revenue on R&D for the year ended March 2010View PDF
April 28, 2010Suven Life Sciences secures Product Patents from India and New ZealandView PDF
April 22, 2010Suven Life Sciences secures Three Australian Patents on NCEsView PDF
April 12, 2010Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE toView PDF
March 29, 2010Suven Life Sciences secures 8th Product Patent from European Patent Office (EPO) for their NCE to trView PDF
March 22, 2010Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat CentralView PDF
January 27, 2010Suven spends 34% of Revenue on R&D for the 3rd quarter ending Dec’ 09View PDF
January 12, 2010Suven Secures Two product patents in China and RussiaView PDF

2009

December 14, 2009Suven Secures two Product patents from Canadian Intellectual Property OfficeView PDF
November 30, 2009Suven Life Sciences secures Three European Patents on NCEsView PDF
October 31, 2009Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09View PDF
October 20, 2009Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual MeView PDF
October 14, 2009Suven’s Clinical Candidate SUVN-502 For Alzheimer’s disease Secures product patents in several Key mView PDF
September 14, 2009Suven Life Sciences secures Two US Patents on NCEsView PDF
September 07, 2009Suven achieves 1st Milestone payment in Drug Discovery collaborationView PDF
July 28, 2009Suven’s profit up by 37%, Spends 22% of Revenue on R&D.View PDF
July 27, 2009Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer’s disease at ICAD 2009, VieView PDF
May 06, 2009SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.View PDF
April 29, 2009Suven’s revenue up by 19%, Spends 22% of Revenue on R&D.View PDF
April 09, 2009Suven completes Phase I Clinical Trials Multiple Ascending Dose of SUVN-502 in Switzerland.View PDF
January 19, 2009Suven’s revenue up by 21%, Spends 24% of Revenue on R&D.View PDF
January 13, 2009Suven participation at Biotech Showcase 2009.View PDF

2008

November 18, 2008Suven participation at Bio-Europe 2008.View PDF
November 11, 2008Suven Presentation at Rodman & Renshaw 10th Annual Healthcare Conference at New York being held fromView PDF
October 31, 2008Suven's net up by 50%, Spends 17% of Revenue on R&DView PDF
October 13, 2008SUVN-502 data being presented at 16th BioPartnering in LondonView PDF
September 29, 2008Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in SwitzerlandView PDF
September 25, 2008DCGI nod to conduct Phase-I Clinical Trials of SUVN-502 for Alzheimer’s diseaseView PDF
August 18, 2008Suven granted Certificate of Suitability (CEP) for Tamsulosin HydrochlorideView PDF
August 04, 2008Suven Life Sciences Presents Positive Preclinical Data for SUVN-502 at Alzheimer’s conference, ChicaView PDF
July 25, 2008Revenue growth for quarter at 11.43%, Commences Phase 1 clinical trial of SUVN-502 in Switzerland foView PDF
July 07, 2008Suven Life Sciences Clinical candidate SUVN-502 being presented at International Conference on AlzheView PDF
June 18, 2008Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s diseaseView PDF
May 27, 2008Suven Life Sciences gets Two product patents for NCEs in Russia and AustraliaView PDF
May 27, 2008Suven Life Sciences gets Two product patents for NCEs in Russia and AustraliaView PDF
May 20, 2008Suven Life Sciences gets Two product patents for NCEs in South Africa and ChinaView PDF
May 05, 2008Suven's Clinical Candidate SUVN-502 Secures European Product PatentView PDF
March 31, 2008Suven Life Sciences gets Two Product patents in Korea and MexicoView PDF
March 24, 2008Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region)View PDF
March 12, 2008Suven Establishes second CNS Drug Discovery Collaboration with LillyView PDF
January 28, 2008Suven Revenue stands flat, R&D spent at 25% of Revenue obtains 2 US, 3 European and 4 Indian ProductView PDF
January 23, 2008Suven obtains 2nd Product Patent from US Patent officeView PDF

2007

December 27, 2007Suven obtains 1st Product Patent from US Patent officeView PDF
December 11, 2007Suven presenting at Windhover's Bio/Pharma Partnerships conference in San FranciscoView PDF
November 27, 2007Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatmentView PDF
November 05, 2007-Suven Life Sciences presenting Pre-clinical data of their NCE's at Society for Neuroscience AnnualView PDF
October 31, 2007Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for their New ChemicaView PDF
October 30, 2007Suven's half yearly revenues increase by 10%, R&D spent at 26% of RevenueView PDF
October 25, 2007Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infectionView PDF
October 23, 2007Suven Life Sciences Secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs)View PDF
July 31, 2007Suven PAT up by 51%;R&D spend at 33% of RevenueView PDF
July 12, 2007Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 iView PDF
July 05, 2007Suven Life Sciences presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507 at InternationView PDF
June 11, 2007-Suven's unit III receives US FDA acceptanceView PDF
April 26, 2007Suven yearly revenues increase by 38%, PAT up by 33% ; R&D spend at 24% of RevenueView PDF
January 29, 2007Suven Income up by 35%, Spends 17% on R&D -Suven shares split from Rs 2 per share to Re. 1 per shareView PDF
January 01, 2007Suven renewed ISO 14001 certificationView PDF
January 01, 2007Suven renewed ISO 9001 certificationView PDF
January 01, 2007Suven received OHSAS 18001 certificationView PDF

2006

September 20, 2006Suven receives NABL certificationView PDF
August 29, 2006Suven and Lilly Establish Drug Discovery CollaborationView PDF
August 16, 2006Preclinical Data on Suven’s 5-HT6 antagonists for CNS diseases to be presented at Neuroscience 2006View PDF
July 31, 2006SUVEN’s quarterly revenues increase by 60%, PAT up by 51%; R&D spend at 16% of RevenueView PDF

2005

November 21, 2005Suven Life Sciences presented Pre-clinical data of their NCEs at Society for Neuroscience (SFN) AnnuView PDF
October 11, 2005Suven Awarded Phase III Clinical study for Chronic Low Back pain.View PDF
October 03, 2005Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & SullivanView PDF

2004

December 14, 2004Suven Life Sciences ropes in global contract research industry veteranView PDF
October 12, 2004Suven pharma promoter invests $1-m in CRO, data developmentView PDF
April 27, 2004Suven Life income up 10 p.c.View PDF
April 23, 2004Suven Life Sciences net Income up by 27.76%View PDF
March 24, 2004Suven to set up Rs 100 cr unit in VizagView PDF
February 05, 2004Suven Life Sciences net up 57 percentView PDF
February 01, 2004Suven profit up 5% to Rs. 1.91 cr in Q3View PDF
January 01, 2004Suven gets ISO 14001 certificationView PDF

2003

December 18, 2003Suven Life to raise Rs 27.4 cr through preferential issue Borregaard exits Suven Life SciencesView PDF
December 05, 2003Suven board okays merger of subsidiary Suven Life board decides to split sharesView PDF
November 28, 2003Suven board to consider merger of subsidiarySuven Life Sciences may merge arm with selfSuven plans pView PDF
November 24, 2003Suven graduating itself to life sciences playerView PDF
October 23, 2003The $15 billion bulk drug opportunityCPhI: Downpour of dealsView PDF
September 29, 2003Venkat Jasti re-elected president of BDMAView PDF
September 06, 2003Spurious drugs eating into AP’s export shareView PDF
August 07, 2003Suven Pharma rechristened Suven LifeView PDF
August 02, 2003Suven Pharma is Suven Life nowView PDF
August 01, 2003Suven Q1 net up 63% at Rs 2.3 crView PDF
July 07, 2003PA fellowship AwardView PDF
June 12, 2003Venkat Jasti asks Govt. & Industry to play pro-active role to tap the potential post-2005View PDF
June 02, 2003Venkat Jasti joins Pharmabiz advisory boardView PDF
May 20, 2003SUVEN Pharma acquires assets of New Jersey (USA) based SYNTHON CHIRAGENICSView PDF
April 26, 2003SUVEN spent 21 % of its revenue in R & DView PDF
April 21, 2003SUVEN eyes discovery researchView PDF
March 25, 2003Drug discovery boutique set up 3 Indian Pharma form allianceDesi Pharma trio ally for new patent regView PDF

2002

December 24, 2002SUVEN Pharma sees revenue jump after April 2004View PDF
October 18, 2002SUVEN starts research academySUVEN Pharma to collaborate in promoting the Centre of Excellence in clView PDF
August 07, 2002SUVEN sets the stage for Contract Research in IndiaView PDF
June 03, 2002Speeding up drug discoveryView PDF

2001

December 25, 2001Pharma sector hopes to have Export Promotion Council soon Andhra Pradesh to set up Pharma CityView PDF
December 24, 2001After IT and BT, Pharma catches Chandrababu Naidu's eyeForget IT, Pharma is the new mantraPharmaexciView PDF
December 23, 2001Pharma City in VizagView PDF
December 21, 2001Vizag's Pharma City to get a booster doseVizag Pharma City Phase-I to be operational by 2003View PDF
November 23, 2001A.P. to attract global majors as healthcare capitalView PDF
November 01, 2001SUVEN PharmaView PDF

Back